Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
Inspira Technologies OXY B.H.N. Ltd. IINN reached a significant milestone with the submission of its INSPIRA ART100 for approval under the Israeli Ministry of Health's AMAR regulation. This regulatory progress is poised to open doors to new markets, particularly in Southeast Asia and South America, paving the way for remarkable growth opportunities for the company.
AMAR is the Israeli Ministry of Health's medical device regulation unit. This authority is responsible for controlling medical device licenses and approvals in the Southeast Asia and South American markets.
More Into the News
The AMAR submission marks a strategic move by Inspira Technologies, positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART). This technology, designed to treat patients without mechanical ventilation while awake, represents a radical advancement in life support systems.
Inspira Technologies in this regard, highlighted the support from local key opinion leaders. The INSPIRA ART (Gen 2) device — which is under development — promises advanced blood oxygenation capabilities, real-time monitoring and personalized oxygenation control tailored to individual patient needs.
Strategic Implication
The integration of adaptive technology in the INSPIRA ART (Gen 2) device is expected to revolutionize patient care by reducing complications associated with traditional ventilation methods, shortening hospital stays and potentially saving lives. This breakthrough underscores Inspira Technologies' commitment to advancing medical technology and improving patient outcomes on a global scale.
Image Source: Zacks Investment Research
Growing Market Prospects
Going by a Mordor Intelligence report, the Global Respiratory Devices Market is on a steady growth trajectory, estimated at $26.73 billion in 2024 and projected to reach $35.58 billion by 2029, at a CAGR of 5.89%. The initial impact of the COVID-19 pandemic led to market fluctuations, but government initiatives and strategic developments bolstered growth. Factors such as rising respiratory disorders like COPD and asthma, coupled with technological advancements, especially in homecare settings, are driving market expansion.
Price Performance
In the past year, Inspira Technologies’ shares surged 48.1% compared with the industry’s 11.2% increase.
Zacks Rank and Key Picks
Inspira Technologies currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Stryker Corporation (SYK), Cencora, Inc. (COR) and Cardinal Health (CAH). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker, carrying a Zacks Rank #2, reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Cencora, carrying a Zacks Rank #2, reported a first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.
COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.
Cardinal Health, carrying a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Cencora, Inc. (COR) : Free Stock Analysis Report
Inspira Technologies OXY B.H.N. Ltd. (IINN) : Free Stock Analysis Report
